Aurobindo Pharma gets US FDA nod for generic cancer drug Bortezomib
The product is the generic version of Reference Listed Drug (RLD) Velcade of Takeda Pharma
Aurobindo Pharma yesterday said its wholly-owned arm Eugia Pharma Specialties has received final approval from the US health regulator to manufacture and market its generic version of Bortezomib for injection used to treat certain types of cancer. The approval by the US Food and Drug Administration (FDA) is for single-dose vial of Bortezomib for injection of strength 3.5 mg/vial, Aurobindo Pharma said in a regulatory filing. The product is the generic version of Reference Listed Drug (RLD) Velcade of Takeda Pharma.
Edits by EP News Bureau
- Advertisement -
Thanks so much
Many thanks